Avamed Synergy

Avamed Synergy, founded in 2012, is the first Spanish company with the vision to innovate the monitoring and personalised treatment of cancer through clinical imaging, focused on reaching excellence in diagnostic and surgical efficiency with the highest precision. Since 2017, Avamed Synergy has collaborated intensively with consultancy and planning in highly complex oncological pathology and its related surgeries, providing specific services in medical specialties such as neurosurgery, maxillofacial and traumatology. With a commitment to future biomedical engineering, Avamed Synergy decided to define and register the brands of its specific services, thus positioning itself as a reference company and unique in providing valuable information for the surgeon and his medical team (defined tumour structures, precise negative resection margins, calculation of non-standard bone loss, simulations, customised prosthesis design, 3D BioModel printing... etc.).

Avamed Synergy sets as a business objective new developments such as the one that will be implemented in its Fluxus project, with the integration of AI and ML in the management and analysis in oncological diagnosis, as well as in the planning of associated treatments. This innovation proposal will provide the technical basis for the predictive modelling and advanced visualisation capabilities of Fluxus, a project that will be at the forefront of technological advances in medical imaging, assisted by AI and ML to provide unprecedented predictive information on the growth and tumours evolution. These advances not only make this project a unique proposal, but also highlight the opportunity for innovation in the use of cutting-edge technology for clinical applications. Avamed Synergy's workflow is identified with a permanent commitment to scientific transfer and technological innovation in the health sector, consolidating a business model of alliances with biosanitary institutions and adding experience in the sector.

Avamed Synergy is strategically positioned to become a leading company in the prediction and classification of tumour growth in oncology.

Innovation: Part of our ADN is the constant innovation of our technology to improve people's quality life's.

Passion: We are passionate about our work and how technology has become our main ally.

Teamwork: A key value within our organisation, where we share knowledge and work towards a common purpose.

Constancy: Our exit is based in constancy and excellence teamwork with an unwavering will.

Equality: We support equal opportunities policies and promote accessibility to science and technology-related careers.

Commitment: From the first person to join the company to the last, they all share a common value: total commitment to the project.

Family: Although we have grown exponentially, we still consider ourselves to be one big little family.